Novocure
NVCR
Novocure (NVCR) earnings history
Most recent quarter
- Fiscal period
- Q2 2026
- Period end
- Jun 30, 2026
- EPS actual
- −$0.13
- EPS estimate
- −$0.33
- EPS surprise
- +60.78%
- Revenue surprise
- +6.46%
- Revenue
- $183.6M
- Revenue estimate
- $172.4M
- Reported
- Jul 23, 2026
Earnings history
| Period | Reported | EPS estimate | EPS actual | Surprise | Revenue | Filing |
|---|---|---|---|---|---|---|
| Q2 2026 | Jul 23, 2026 | −$0.33 | −$0.13 | +60.78% | $183.6M | SEC |
| Q1 2026 | Apr 30, 2026 | −$0.51 | −$0.62 | −21.05% | $174.1M | SEC |
| Q4 2025 | Feb 26, 2026 | −$0.41 | −$0.22 | +46.52% | $174.3M | SEC |
| Q3 2025 | Oct 30, 2025 | −$0.42 | −$0.33 | +21.37% | $167.2M | SEC |
| Q2 2025 | Jul 24, 2025 | −$0.38 | −$0.36 | +6.27% | $158.8M | SEC |
| Q1 2025 | Apr 24, 2025 | −$0.46 | −$0.31 | +33.20% | $155.0M | SEC |
| Q4 2024 | Feb 27, 2025 | −$0.34 | −$0.61 | −77.17% | $161.3M | SEC |
| Q3 2024 | Oct 30, 2024 | −$0.33 | −$0.28 | +16.12% | $155.1M | SEC |
| Q2 2024 | Jul 25, 2024 | −$0.40 | −$0.31 | +23.06% | $150.4M | SEC |
| Q1 2024 | May 2, 2024 | −$0.42 | −$0.36 | +14.29% | $138.5M | SEC |
| Q4 2023 | Feb 22, 2024 | −$0.52 | −$0.45 | +13.69% | $133.8M | SEC |
| Q3 2023 | Oct 26, 2023 | −$0.53 | −$0.46 | +12.38% | $127.3M | SEC |
| Q2 2023 | Jul 27, 2023 | −$0.50 | −$0.54 | −8.00% | $126.1M | SEC |
| Q1 2023 | May 4, 2023 | −$0.32 | −$0.50 | −54.85% | $122.2M | SEC |
| Q4 2022 | Feb 23, 2023 | −$0.30 | −$0.36 | −19.01% | $128.4M | SEC |
| Q3 2022 | Oct 27, 2022 | −$0.26 | −$0.25 | +4.36% | $131.0M | SEC |
| Q2 2022 | Jul 28, 2022 | −$0.15 | −$0.23 | −58.62% | $140.9M | SEC |
| Q1 2022 | Apr 28, 2022 | −$0.19 | −$0.04 | +78.38% | $137.5M | SEC |
| Q4 2021 | Feb 24, 2022 | −$0.10 | −$0.25 | −143.90% | $133.2M | SEC |
| Q3 2021 | Oct 28, 2021 | −$0.07 | −$0.13 | −76.15% | $133.6M | SEC |
Quarterly revenue
Frequently asked questions
When did Novocure (NVCR) last report earnings?
Novocure last reported on Jul 23, 2026, covering fiscal Q2 2026.
Did NVCR beat earnings estimates?
Yes. Novocure reported EPS of −$0.13 for Q2 2026 against a −$0.33 estimate — a 60.78% beat.
How much revenue did NVCR report last quarter?
Novocure reported $183.6M in revenue for Q2 2026, against a consensus estimate of $172.4M.
Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.